Predict your next investment

Public-Private Partnership
sep.benfranklin.org

See what CB Insights has to offer

Investments

349

Portfolio Exits

49

Funds

6

Partners & Customers

3

Service Providers

2

About Ben Franklin Technology Partners of Southeastern PA

Ben Franklin Technology Partners combines the best practices of early stage investing with a higher purpose – to lead the region's technology community to new heights, creating jobs and transforming lives. For over 30 years, Ben has been the leading seed stage capital provider for the region's technology sectors, investing over $175 million in more than 1,750 regional technology companies, many of which have gone on to become industry leaders. Ben Franklin has also launched university/industry partnerships that accelerate scientific discoveries to commercialization, and has seeded regional initiatives that strengthen our entrepreneurial community.

Ben Franklin Technology Partners of Southeastern PA Headquarter Location

Building 100 Innovation Center 4801 S. Broad Street, Suite 200

Philadelphia, Pennsylvania, 19112,

United States

215-972-6700

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Ben Franklin Technology Partners of Southeastern PA News

QR Pharma Receives Seed Investment from Ben Franklin Technology Partners for Further Development of Clinical Stage Compounds to Treat Alzheimer’s Disease

Mar 29, 2018

Radnor, PA, April 6, 2009 QR Pharma, Inc., a newly formed specialty pharmaceutical company focused on developing novel therapeutics for the treatment of Alzheimer’s disease, received a $500,000 investment from Ben Franklin Technology Partners of Southeastern PA. The investment will further the clinical development of two lines of compounds, Posiphen® and bisnorcymserine and their respective analogs to treat Alzheimer’s disease (AD) and cognitive impairment. QR Pharma was founded to capitalize on technology that was invented by Dr. Nigel Greig at NIA/NIH, QR Pharma obtained an exclusive worldwide license in November 2008. “The technology targets two critical pathways in the treatment of Alzheimer’s disease and achieves both in a manner that has the potential to impact disease progression and provide symptomatic relief,” said Maria Maccecchini, Ph.D., CEO of QR Pharma and a successful biotechnology veteran in the region. “In the last 6 months we have assembled a world-class team experienced in the strategic development of Alzheimer’s drugs. We are focused on aggressively moving this new technology forward in the clinic to show efficacy in mild as well as severe Alzheimer’s cases.” Alzheimer’s disease is a debilitating condition that accounts for 64% of all dementias, and afflicts more than 30 million people worldwide. Its economic burden and impact on patient wellness and quality of life for both patients and their caregivers are devastating. In the US alone, the estimated direct and indirect annual cost of patient care is over $100 billion. Current Alzheimer’s drugs provide symptomatic relief with limited levels of success, and fail to prevent the progression of the underlying disease. Today, the greatest unmet need is the availability of disease-modifying therapies. Thought leaders believe that targeting the accumulation of amyloid-ß peptide (Aß) that forms into hallmark plaques in the brain will change the course of Alzheimer’s. However, a second hypothesis states that amyloid precursor protein (APP) is instrumental in inducing neuronal cell death before it is processed into Aß. QR’s lead compound, Posiphen®, inhibits APP synthesis in preclinical models and, thereby, reduces A? accumulation into plaque as well as APP induced nerve cell death. Posiphen® is distinct from the Alzheimer’s drugs currently available or in clinical development, because it has a dual mechanism of action: it reduces APP/Aß generation through direct inhibition of APP synthesis, and it may provide symptomatic relief through acetylcholinesterase inhibition (AChEI). Posiphen® was tested in single and multiple ascending dose phase I trials, and found to be safe. The next compound in QR’s pipeline is a preclinical stage compound, bisnorcymserine (BNC). BNC is a centrally active, reversible butyrylcholinesterase inhibitor, and is expected to work in advanced Alzheimer’s, at a stage when little AChE remains in the brain and BChE predominates. Like Posiphen®, BNC has been shown to reduce the generation of APP/Aß in the brain in preclinical models, by lowering the rate of synthesis of APP. “I look forward to further development of these experimental Alzheimer’s drugs,” Dr. Greig noted. “With the aging of our population, it is more critical than ever that we find ways to slow the progression of the disease, or prevent it altogether.” About QR Pharma, Inc About QR Pharma, Inc.: Headquartered in Radnor, Pennsylvania, QR Pharma, Inc. is a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment and Alzheimer’s disease (AD). QR currently has two product development programs based on oral small-molecule, blood-brain barrier passable therapeutics that target two distinct pathways for the treatment of AD. Contact: Maria L. Maccecchini, PhD Tel: 484 253 2296

Ben Franklin Technology Partners of Southeastern PA Investments

349 Investments

Ben Franklin Technology Partners of Southeastern PA has made 349 investments. Their latest investment was in Astarte Medical as part of their Series A - III on September 9, 2021.

CBI Logo

Ben Franklin Technology Partners of Southeastern PA Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/22/2021

Series A - III

Astarte Medical

$7.6M

No

2

8/26/2021

Series A

Vesteck

$4.3M

Yes

3

7/21/2020

Seed VC - III

Yellowdig

$1.5M

Yes

1

1/6/2020

Series A - III

Subscribe to see more

$99M

Subscribe to see more

10

12/3/2019

Unattributed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/22/2021

8/26/2021

7/21/2020

1/6/2020

12/3/2019

Round

Series A - III

Series A

Seed VC - III

Series A - III

Unattributed VC

Company

Astarte Medical

Vesteck

Yellowdig

Subscribe to see more

Subscribe to see more

Amount

$7.6M

$4.3M

$1.5M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

3

1

10

10

Ben Franklin Technology Partners of Southeastern PA Portfolio Exits

49 Portfolio Exits

Ben Franklin Technology Partners of Southeastern PA has 49 portfolio exits. Their latest portfolio exit was LoanLogics on July 07, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/7/2021

Acq - Fin

2

6/10/2021

Acquired

11

5/26/2021

Acq - Fin

6

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

7/7/2021

6/10/2021

5/26/2021

00/00/0000

00/00/0000

Exit

Acq - Fin

Acquired

Acq - Fin

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

Acquirer

Subscribe to see more

Subscribe to see more

Sources

2

11

6

10

10

Ben Franklin Technology Partners of Southeastern PA Fund History

6 Fund Histories

Ben Franklin Technology Partners of Southeastern PA has 6 funds, including Global Opportunity Philadelphia Fund I.

Closing Date

Fund

Fund Type

Status

Amount

Sources

2/7/2019

Global Opportunity Philadelphia Fund I

$25M

5

2/7/2019

Global Opportunity Philadelphia Fund

Subscribe to see more

$99M

10

4/17/2018

Venture Chesco

Subscribe to see more

$99M

10

3/21/2007

Gap Fund

Subscribe to see more

$99M

10

Drexel and Ben Franklin Seed Fund

Subscribe to see more

$99M

10

Closing Date

2/7/2019

2/7/2019

4/17/2018

3/21/2007

Fund

Global Opportunity Philadelphia Fund I

Global Opportunity Philadelphia Fund

Venture Chesco

Gap Fund

Drexel and Ben Franklin Seed Fund

Fund Type

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Amount

$25M

$99M

$99M

$99M

$99M

Sources

5

10

10

10

10

Ben Franklin Technology Partners of Southeastern PA Partners & Customers

3 Partners and customers

Ben Franklin Technology Partners of Southeastern PA has 3 strategic partners and customers. Ben Franklin Technology Partners of Southeastern PA recently partnered with Wistar Institute on April 4, 2018.

Date

Type

Business Partner

Country

News Snippet

Sources

4/27/2018

Partner

Wistar Institute

United States

Wistar and Ben Franklin Technology Partners of Southeastern Pa. Forge Collaboration to Accelerate Technology Commercialization.

`` The Wistar Institute and Ben Franklin collaboration brings together exceptional science , future product opportunities , talent and seed funding to ignite entrepreneurialism in our life sciences community '' said Heather Steinman , Ph.D. , MBA , Vice President for Business Development and Executive Director of Technology Transfer at Wistar Institute , `` We are very pleased to be working closely with Ben Franklin . ''

1

5/27/2016

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

7/7/2011

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

4/27/2018

5/27/2016

7/7/2011

Type

Partner

Partner

Partner

Business Partner

Wistar Institute

Country

United States

Subscribe to see more

Subscribe to see more

News Snippet

Wistar and Ben Franklin Technology Partners of Southeastern Pa. Forge Collaboration to Accelerate Technology Commercialization.

`` The Wistar Institute and Ben Franklin collaboration brings together exceptional science , future product opportunities , talent and seed funding to ignite entrepreneurialism in our life sciences community '' said Heather Steinman , Ph.D. , MBA , Vice President for Business Development and Executive Director of Technology Transfer at Wistar Institute , `` We are very pleased to be working closely with Ben Franklin . ''

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

Ben Franklin Technology Partners of Southeastern PA Service Providers

2 Service Providers

Ben Franklin Technology Partners of Southeastern PA has 2 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Associated Rounds

Subscribe to see more

Provider Type

Counsel

Subscribe to see more

Service Type

Subscribe to see more

Partnership data by VentureSource

Ben Franklin Technology Partners of Southeastern PA Team

4 Team Members

Ben Franklin Technology Partners of Southeastern PA has 4 team members, including current Chief Executive Officer, President, RoseAnn B Rosenthal.

Name

Work History

Title

Status

RoseAnn B Rosenthal

Chief Executive Officer, President

Current

Adare McMillan

Chief Administrative Officer

Current

Jennifer Hart

Managing Director

Current

Bill Harrington

Executive Vice President

Former

Name

RoseAnn B Rosenthal

Adare McMillan

Jennifer Hart

Bill Harrington

Work History

Title

Chief Executive Officer, President

Chief Administrative Officer

Managing Director

Executive Vice President

Status

Current

Current

Current

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.